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A B S T R A C T
UVA accounts for about 95% of the solar ultraviolet (UV) radiation that reaches Earth and most likely
contributes to human skin cancer risk. In contrast to UVB, which comprises the remaining 5% and is absorbed
by DNA nucleobases to cause direct photodamage, UVA damages DNA indirectly. It does this largely through its
interactions with cellular chromophores that act as photosensitisers to generate reactive oxygen species.
Exogenously supplied chemicals, including some widely-prescribed medicines, may also act as photosensitisers
and these drugs are associated with an increased risk of sun-related cancer. Because they amplify the eﬀects of
UVA on cells, they provide a means to investigate the mechanisms and eﬀects of UVA-induced photodamage.
Here, we describe some of the major lesions induced by two groups of UVA photosensitisers, the DNA
thionucleotides and the ﬂuoroquinolone antibiotics. In thionucleotides, replacement of the oxygen atoms of
canonical nucleobases by sulfur converts them into strong UVA chromophores that can be incorporated into
DNA. The ﬂuoroquinolones are also UVA chromophores. They are not incorporated into DNA and induce a
diﬀerent range of DNA damages. We also draw attention to the potentially important contribution of
photochemical protein damage to the cellular eﬀects of photosensitised UVA. Proteins targeted for oxidation
damage include DNA repair factors and we suggest that UVA-mediated protein damage may contribute to
sunlight-induced cancer risk.
1. Introduction
UVA (wavelengths 320–400 nm) comprises more than 95% of the
solar UV radiation that reaches Earth, making it far more abundant
than UVB (280–320 nm) that accounts for the remainder. Most of UVB
and all of UVC (wavelengths below 280 nm) are removed by the ozone
layer and these shorter wavelengths are not present in incident
sunlight. UVA is classiﬁed as “probably carcinogenic to humans” by
WHO IARC [1] although, unlike UVC and UVB, it is absorbed poorly by
canonical nucleotides and therefore causes much less damage to
cellular DNA [2]. UVA-mediated DNA damage occurs partly by indirect
mechanisms via interactions with cellular chromophores that act as
photosensitisers to generate DNA-damaging reactive oxygen species
(ROS). Depending on the distance between the chromophore and the
target, UVA irradiation can also result in one-electron abstraction and
the formation of a reactive radical cation. Importantly, UVA-generated
ROS damage other biomolecules including proteins and lipids, and this
non-DNA photodamage may be an important contributor to the
biological eﬀects of UVA such as carcinogenesis and photoaging.
Endogenous UVA chromophores have not been fully characterized,
although porphyrins, ﬂavins [3], melanin [4] and UVB photoproducts
of tryptophan (6-formylindolo[3,2-b]carbazole, FICZ) [5] are among
the potential candidates. Studies employing exogenous UVA chromo-
phores that mimic and amplify the eﬀects of their endogenous counter-
parts, provide a useful strategy to investigate events associated with
UVA photosensitisers. Many of these chemicals have been used in
various aspects of nucleic acid research. More importantly, some are
widely-prescribed pharmaceuticals and their use is associated with an
increased skin cancer risk. All these drugs have signiﬁcant UVA
absorbance and sensitise the formation of a variety of DNA and protein
lesions. Although generally non-toxic, their foremost unifying feature is
an extreme cytotoxicity in combination with low doses of UVA. This
review will discuss DNA damage induced by photoactivation of
thiopurines, thiopyrimidines and the ﬂuoroquinolone group of anti-
biotics. We will also consider potentially important eﬀects of photo-
chemical damage to the proteome – particularly to DNA repair
proteins.
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2. UVA photosensitisers
i) Thiopurines
The thiopurines azathioprine, mercaptopurine and 6-thiogua-
nine (6-TG) (Fig. 1A) are eﬀective anticancer, anti-inﬂammatory
and immunosuppressant drugs (reviewed in [6]). They are all
prodrugs that undergo enzymatic conversion that culminates in the
formation of the thiopurine nucleotides that are an absolute
requirement for their clinical eﬀectiveness. Despite more than half
a century of clinical use, the molecular events underlying thiopur-
ine cytotoxicity are still not fully understood. Suggested mechan-
isms include inhibition of de novo purine synthesis resulting in an
inadequate supply of purine nucleotides for replication and
transcription [7] and interference with intracellular signalling
pathways via competition for GTP binding by G proteins [8,9].
Thioguanine nucleotides are substrates for incorporation into DNA
and to a lesser degree into RNA and the biological eﬀects of
thiopurines are at least partly dependent on the formation of DNA
6-TG [7,10]. DNA 6-TG may undergo in situ non-enzymatic
methylation that can provoke ultimately lethal processing by
DNA mismatch repair [11,12]. Alternatively, it can participate in
the formation of DNA interstrand-crosslinks [13] that are highly
toxic in a mismatch repair-independent manner. The methylated
form of DNA 6-TG miscodes during replication and it is note-
worthy that azathioprine treatment is associated with a perceptible
increase in mutation frequency in circulating lymphocytes [14] and
with an increased risk of leukemia [12]. Most striking, however, is
the greater than 100-fold higher risk of skin cancer in immuno-
suppressed organ transplant patients [15], most of whom will have
been prescribed azathioprine and whose skin contains detectable
amounts of DNA 6-TG [16]. Its more intermittent use in the
management of inﬂammatory bowel disease entails a lower, but
still signiﬁcant skin cancer risk [17–19]. Sunlight exposure is a
contributory factor in thiopurine-related skin cancer. The skin of
patients taking azathioprine is photosensitive to UVA but not to
UVB, consistent with the absorbance maximum of DNA 6-TG at
around 340 nm. This has led to the suggestion that the photo-
chemical reactions of azathioprine or its metabolites [20] may
contribute to skin cancer risk [21].
ii) Thiopyrimidines
4-Thiothymine (S4T) is not currently used clinically although it
has been proposed as a potential UVA photosensitiser for treat-
ment of skin malignancies [22,23]. Like 6-TG, S4T is derived from
a canonical DNA base in which the replacement of a single oxygen
atom by sulfur converts it to a UVA chromophore and S4T has an
absorbance maximum at 335 nm. The S4T deoxyribonucleoside, 4-
thiothymidine (S4dT) (Fig. 1B), is a good substrate for thymidine
kinase (TK) and S4T is extensively incorporated into DNA of cells
treated with S4dT via the TK-dependent pyrimidine nucleoside
salvage pathway [24]. Despite its accumulation to higher levels
than DNA 6-TG and the ability to undergo facile in situ methyla-
tion, DNA S4T is not detectably toxic. The absence of cytotoxicity
has been ascribed to the preferential formation of structurally and
thermodynamically good base pairs by both DNA S4T and its
methylated counterpart that obviates their engagement by DNA
mismatch repair, the major contributor to DNA 6-TG toxicity [25].
DNA S4T is, however, extremely cytotoxic in combination with low
doses of UVA [24]. Recently, 2,4-dithiothymidine has been shown
to be comparable or superior to 4-thiothymidine as a photosensi-
tiser in solution and it is cytotoxic in combination with UVA
[26,27].
The halopyrimidine nucleosides 5-iodo-2′-deoxyuridine (IdU)
Fig. 1. Structures of UVA photosensitisers. Azathioprine, mercaptopurine and 6-thioguanine are all converted to 6-TG deoxyribonucleotides, which are in turn incorporated into DNA.
This is a prerequisite for the clinical eﬀectiveness of thiopurines. Thiopyrimidine deoxynucleosides are incorporated into DNA of cells via the TK-dependent pyrimidine nucleoside
salvage pathway. The ﬂuoroquinolone class of antibiotics acts as inhibitors of DNA topoisomerases and intercalate rather than incorporate into DNA.
R. Brem et al. Free Radical Biology and Medicine xx (xxxx) xxxx–xxxx
2
and 5-bromo-2′-deoxyuridine (BrdU) are also thymidine analogs.
They are used extensively to label DNA where they can be detected
by ﬂuorescent antibodies or by an induced shift in DNA buoyant
density. Although they retain the absorbance characteristics of the
parent thymidine with maximal absorbance in the UVC range, the
replacement of the methyl group with I or Br alters their reactivity.
DNA IdU and BrdU are photoactive and synergistically enhance
the toxicity of UVC and UVB [28,29]. When activated by short
wavelength UV, DNA-embedded IdU or BrdU induce potentially
lethal DNA lesions such as strand breaks [30], DNA interstrand
crosslinks (ICLs) [31] and DNA protein crosslinks (DPCs) [32].
DNA halopyrimidines also sensitise cells to UVA wavelengths when
they are combined with the DNA-intercalating Hoechst dye that
serves as a surrogate UVA chromophore [33]. The synergistic
cytotoxicity of halopyrimidine/Hoechst/UVA combinations led to
the development of thio analogs of IdU and BrdU, 5-iodo-4-thio-
2′-deoxyuridine (SIdU) and 5-bromo-4-thio-2′-deoxyuridine
(SBrdU) [34,35] (Fig. 1B). As anticipated, SIdU and SBrdU are
UVA chromophores with an absorbance maximum at around
340 nm. They are salvaged reasonably well for incorporation into
DNA and are minimally toxic. When combined with UVA, however,
DNA-embedded halothiopyrimidines induce a spectrum of poten-
tially lethal DNA damage that does not require the participation of
Hoechst dye [36].
iii) Fluoroquinolones
The ﬂuoroquinolones including ciproﬂoxacin, oﬂoxacin and
lomeﬂoxacin (Fig. 1C) are among the most extensively prescribed
antibiotic drugs worldwide. Fluoroquinolones are acknowledged
photosensitisers [37] with both UVA and UVB absorbance maxima.
In combination with UVA, they are photocarcinogens in mice
[38,39] and are associated with adverse skin reactions and an
increase of pre-malignant skin lesions in patients [40–44]. The
bactericidal eﬀect of the ﬂuoroquinolones reﬂects inhibition of
DNA gyrase and topoisomerase IV [45]. They are not toxic to
human cells although they are synergistically cytotoxic when
combined with low doses of UVA.
3. UVA photosensitisation
UVA photosensitisation occurs by two main mechanisms that can
trigger one-electron oxidation of suitable substrates (Type I) and/or
generate various reactive oxygen species (ROS) including superoxide
(O2
•-, by Type I) or singlet oxygen (1O2) (Type II) [46,47]. Following
UVA excitation of the chromophore, Type I reactions generate a pair of
charged radicals (a photosensitiser anion and a target cation). Both
radicals can undergo further reactions to produce oxygenated products.
In the case of guanine, for example, the related cation may undergo
hydration reactions which gives rise to the 8-hydroxy-7,8-dihydrogua-
nyl radical which upon one-electron oxidation mediated by molecular
oxygen results in the formation of 8-oxo-7,8-dihydroguanine (8-
oxoGua). Alternatively, the photosensitiser anion may be oxidised back
by O2 in a reaction which generates O2
•-. Enzymatic dismutation of O2
•-
generates H2O2 which although relatively unreactive, is freely diﬀusible
throughout the cell and can generate highly destructive hydroxyl
radicals (•OH) via metal catalysed reactions. In Type II reactions, the
energy absorbed by the chromophore is transferred directly to mole-
cular oxygen to generate 1O2, a relatively long-lived ROS. In canonical
DNA, 1O2 targets exclusively DNA guanine to generate 8-oxoGua
[48,49].
4. Nucleobase photoproducts
i) 6-Thioguanine
The mechanism by which the ultimate thiopurine metabolite,
DNA 6-TG, exerts its photochemical eﬀects, is still a matter of
debate. Several studies have implicated 1O2 generated by a Type II
photosensitisation in photochemical DNA damage mediated by 6-
TG [50–53]. A recent study [54] which revealed a much lower 1O2
yield than previously reported, questions the dominance of 1O2 in
6-TG-mediated photo-oxidation. DNA 6-TG itself is a major target
of photochemically generated ROS because its oxidation potential
is lower than that of canonical DNA bases. Guanine-6-sulﬁnate
(GSO2) and guanine-6-sulfonate (GSO3) (Fig. 2A) were originally
identiﬁed as oxidation products of 6-TG in free solution [55].
Fig. 2. UVA photoproducts of DNA 6-thioguanine (6-TG) and 4-thiothymidine A. 6-TG. Reactive oxygen species generated from the interaction between 6-TG and UVA oxidise 6-TG or
DNA 6-TG to guanine sulﬁnate and sulfonate as predominant products. These oxidised forms are also produced by MMPP treatment of 6-TG-substituted DNA. B.Potential intrastrand
crosslink between DNA 6-TG and an adjacent imidazole ring-opened deoxyadenosine. UVA-mediated generation of covalent adducts of this type between 6-thioinosine and
deoxyadenosine has been demonstrated in solution. C.4-thiothymidine. The thietane photoproduct generated by interstrand crosslinking between DNA 4-thiothymidine and a 5’-DNA
thymidine.
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Complete UVA-mediated degradation of 6-TG in aqueous solution
yields GSO2 as the major photoproduct (60%) and minor amounts
of GSO3, guanine and guanine-6-thioguanine (a 6-TG addition
product) [56]. These reactions are dependent on molecular oxygen
and involve Type II photosensitisation [51,52]. DNA GSO2 and
GSO3 are also the major products when double-stranded DNA
containing 6-TG is UVA irradiated or treated with magnesium
monoperoxyphthalate (MMPP), a mild oxidising agent that is able
to oxidise DNA 6-TG but not the canonical DNA bases [52]. GSO2
and GSO3 comprise more than 90% of identiﬁed DNA 6-TG
photoproducts at low and medium UVA doses. Increasing UVA
doses result in higher GSO3 recovery, concomitant with decreased
GSO2 levels [56]. The photochemistry of DNA 6-TG is thus
consistent with sequential oxidation to DNA GSO3 via guanine
sulfenate (GSO) and GSO2. GSO3 cannot be oxidised further
[50,57]. A postulated GSO intermediate is not observed. This
may reﬂect its instability although the possible formation of
GSO2 and GSO3 via an initial peroxy intermediate [58] has not
been excluded.
The formation of UVA-mediated intrastrand crosslinks between
DNA 6-TG and neighbouring nucleotides has not been demon-
strated. The generation of DNA 6-TG:A addition products is
plausible based on the known photoaddition reaction between 6-
TG and 2’-deoxyadenosine containing an opened imidazole ring in
solution [59,60], although this reaction might be disfavoured in
DNA by steric constraints (Fig. 2B).
Oxidised forms of 6-TG are bulky lesions and, like intrastrand
crosslinks, they distort and destabilize the DNA helix. This
property makes them potential targets for removal by nucleotide
excision repair (NER) that rids DNA of this type of damage. DNA
GSO3 is not actively removed, however, and NER-deﬁcient cells are
not hypersensitive to treatment with 6-TG+UVA [10,16]. These
ﬁndings suggest that 6-TG+UVA does not generate potentially
lethal NER substrates. It should be noted, however, that NER is
impaired by the protein oxidation induced by 6-TG+UVA [61].
This photochemical protein damage provides an alternative ex-
planation for the persistence of DNA GSO3 and the absence of
sensitivity of NER-deﬁcient cells.
ii) Thiothymidine
When S4dT is UVA irradiated in dilute aqueous solution, the
major reaction is hydrolysis to dT. Small amounts of thymidine
sulfenate (TSO) and a dimeric form, tentatively identiﬁed as T-S-T,
are also produced. dT is not a signiﬁcant photoproduct of DNA
S4dT, however, and it is not detected in irradiated double-stranded
oligonucleotides [62]. Degradation of DNA-embedded S4T is
heavily dependent on sequence context. It is atypically photosen-
sitive when placed 3’ to thymine. The reason for this selective
photosensitivity is the preferential formation of DNA intrastrand
crosslinks between 5’-T and 3’-S4T. Based on its behaviour on RP-
HPLC, ﬂuorescence spectrum and recognition by speciﬁc antibo-
dies, the crosslinked species was identiﬁed as a thietane, S5-(6-4
TT), the thio analog of the related oxetane pyrimidine (6-4)-
pyrimidone (6-4 TT), a DNA photoproduct of both UVC and
UVB (Fig. 2C). Unlike the UVC-induced oxetane which rapidly
converts into a ring-open form, the thietane is more stable and the
ring-closed structure is favoured. Thietanes were detected in
human cells treated with S4dT /UVA and they were repaired by
NER, albeit somewhat more slowly than canonical pyrimidine (6-
4)-pyrimidone (6-4 PP) photoproducts. DNA thietanes are there-
fore likely to be signiﬁcant contributors to the particular S4dT/UVA
sensitivity of NER-deﬁcient XPA cells [24,62]. In contrast to 6-TG,
ROS do not appear to contribute signiﬁcantly to the phototoxicity
of S4dT at low UVA doses [62]. Paradoxically, however, UVA
irradiation of S4dT in solution yielded similar (or higher) 1O2 yields
to irradiated 6-TG [26,63].
iii) Halothiopyrimidines
UVA degrades SIdU both in free solution and in DNA. An initial
UVA-induced deiodination gives rise to a thiouracil-5-yl radical
that can be further converted to SdU. Higher UVA doses generate
2’-deoxyuridine (dU). dU formation most likely proceeds via an
oxidised thiol intermediate as treatment of authentic SdU with
MMPP also generates dU and an intermediate with the same
properties is detectable after irradiation of either SIdU or SdU
(Fig. 3). In DNA, thiouracil-5-yl radicals derived from SIdU can
react further to generate DNA strand-breaks, ICLs or DPCs (see
below). Irradiation of cells containing DNA SIdU also produces a
non-toxic DNA lesion, most likely uracil, that is a substrate for the
uracil DNA glycosylase (UNG) [36].
Consistent with the relative stability of the C5-Br bond, UVA
irradiation of SBrdU does not induce signiﬁcant debromination.
SBrdU in solution is nevertheless completely degraded by UVA and
small amounts of BrdU are formed. UVA-mediated degradation of
SBrdU coincides with the formation of an ephemeral intermediate
that disappears concomitantly with BrdU formation (Fig. 4). As
with SdU, MMPP treatment mimics the eﬀects of UVA and is
consistent with BrdU formation via S4 oxidation and loss of the
oxidised thiol group. The eﬀect of UVA on DNA-embedded SBrdU
is very diﬀerent. Approximately 50% of DNA SBrdU is degraded by
very low UVA doses whereas the remainder is much more
refractory even at high doses. Whether this diﬀerential sensitivity
to degradation reﬂects the eﬀects of particular sequence contexts is
currently unclear. BrdU formation is not observed, possibly due to
preferential reactions between the oxidised thiol group and other
DNA nucleobases or proteins (to form ICLs and DPCs, respec-
tively). UNG-deﬁcient cells are sensitive to SBrdU/UVA, indicating
that this combination also induces unidentiﬁed potentially lethal
DNA lesions that are substrates for excision by UNG [36].
NER defective cells are hypersensitive to both SBrdU/UVA and
Fig. 3. UVA photoproducts of 4-thio-5-iododeoxyuridine (SIdU). UVA irradiation of free SIdU in solution or of DNA containing incorporated SIdU causes deiodination and the
generation of SdU via a reactive a 5-thiyl radical. Further reactions induced by UVA or MMPP generate (unidentiﬁed) thiol-oxidised intermediates – possibly the sulﬁnate [bracketed].
The intermediate(s) can undergo loss of the thiol group to generate dU as a ﬁnal product. The thiyl radical and the oxidised thiol DNA intermediates can also react with nucleobases on
the complementary DNA strand to generate DNA interstrand crosslinks (ICLs) or potentially with protein functional groups to form DNA-protein crosslinks (DPCs).
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SIdU/UVA. This indicates that these combinations induce poten-
tially lethal DNA photolesions that most likely resemble S5-(6-4)TT
and the canonical UV (6-4)PP photoproducts [36].
iv) Fluoroquinolones
Fluoroquinolones do not become covalently incorporated into
DNA. They can, however, enhance the formation of canonical DNA
lesions. UVC and UVB induce several diﬀerent DNA cyclobutane
pyrimidine dimers (CPDs) by direct photon absorbance. UVA
generates exclusively thymine < > thymine (T < > T) CPDs most
likely predominantly by triplet energy transfer from excited cellular
chromophores to DNA thymine [47]. Some (examples include
lomeﬂoxacin and ciproﬂoxacin), but not all (oﬂoxacin and ruﬂox-
acin) UVA-excited ﬂuoroquinolones have suﬃciently high triplet
energy levels to mediate T < > T formation by an analogous triplet
energy transfer [64,65]. (6-4)PP photoproducts are not formed by
these mechanisms.
5. DNA interstrand crosslinks (ICLs)
ICLs are highly cytotoxic lesions. In combination with UVA, 6-TG,
S4T and the halothiopyrimidines all induce ICLs in duplex oligonucleo-
tides in vitro [36,62,66], indicating that thionucleotides have the
potential to form ICLs in vivo.
ICLs in living cells are processed by the Fanconi Anemia (FA)
pathway, homologous recombination, NER and translesion DNA
synthesis which together eﬀect their repair. FA cells are hypersensitive
to crosslinking agents and their response is considered diagnostic for
ICL induction since an active FA pathway is essential for ICL repair.
Monoubiquitination of the FANCD2 protein is a key step in FA pathway
activation and provides a sensitive indicator of the presence of ICLs.
UVA irradiation of cells treated with 6-TG, S4dT or the halothiopyr-
imidine deoxynucleosides induces monoubiquitination of FANCD2 and
FA cells are hypersensitive to all these drug/UVA combinations
[13,36,62].
i) 6-Thioguanine
UVA induces eﬃcient crosslinking of double-stranded oligonu-
cleotides heavily substituted with 6-TG [66]. In these model
substrates, most ICLs are formed via disulﬁde bridges and cross-
linking is signiﬁcantly enhanced by closely opposed 6-TGs. A
minority of ICLs involve 6-TG linkage to a normal base via a single
sulfur atom. These ICLs most likely predominate in UVA-irradiated
cells with sparsely distributed DNA 6-TG. Their formation may
involve generation of a thiyl radical in a Type I photosensitisation
followed by reactions with nucleobase amino groups.
In cells, 6-TG induces ICLs even without UVA treatment. FA
cells are hypersensitive to 6-TG concentrations that induce
FANCD2 ubiquitination in wild-type cells [66,67]. Treatment with
6-TG depletes cellular antioxidant defences and cause an increase
in steady-state levels of ROS. ROS induce ICLs by targeting DNA-
embedded 6-TG [13]. Because antioxidant depletion is expected to
increase steady-state O2
•- and H2O2 levels and subsequently to
generate •OH, it is likely that 6-TG-induced ICLs may be generated
via the formation of thiyl radicals, but the crosslinking mechanism
has not been elucidated. The intense ROS burst that accompanies
UVA irradiation further increases ICL formation. 6-TG- and 6-TG/
UVA-induced ICLs are easily detectable by physicochemical meth-
ods such as the comet assay. Their formation can also be inferred
from the chromosome aberrations present in the karyotypes of
treated cells. The observed radial chromosomes and chromosome
breaks are characteristically associated with aberrantly resolved
ICLs [66].
ii) Thiothymidine
UVA also crosslinks duplex oligonucletides containing S4T. ICL
formation is largely independent of sequence context although it is
less eﬃcient when S4T has a ﬂanking T, most likely because of the
preferential formation of intrastrand photoproducts [62]. UVA-
induced crosslinking is between S4T and the complementary A. It is
abolished when the A is replaced by G and diminished when the
opposed base is inosine or 2-aminopurine.
Treatment with S4dT/UVA (but not S4dT alone) also induces
ICLs in vivo. Low UVA doses (≤10 kJ/m2) induce FANCD2
ubiquitination and ICL formation in cells containing DNA-incorpo-
rated S4T. Consistent with ICL induction, FA cells and cells
defective in XPF, another essential ICL processing factor, are
exquisitely sensitive to DNA S4T/UVA [62]. S4dT /UVA-treated
FA cells also accumulate the characteristic radial chromosomes and
chromosome breaks associated with imperfectly processed ICLs (E.
McAdam, P. Karran, unpublished).
Phosphoramidites of SIdU or SBrdU are not available and this
has precluded examination of crosslinking in synthetic halothio-
base-containing oligonucleotides. However, UVA irradiation of a
double-stranded oligonucleotide containing a single SdU, a photo-
product of SIdU, does induce crosslinking to a complementary A or
Fig. 4. UVA photoproducts of 4-thio-5-bromodeoxyuridine (SBrdU). In free solution, UVA irradiation or MMPP treatment of the deoxynucleoside generates 5-bromodeoxyuridine
(BrdU) via an (unidentiﬁed) oxidised intermediate (shown here as the sulﬁnate). The photochemistry of DNA SBrdU is diﬀerent. UVA-mediated degradation of SBrdU is not followed by
the formation of detectable BrdU. This suggests that reaction with the complementary DNA strand or proteins in preferred. A potentially lethal DNA lesion that is a substrate for the
Escherichia coli uracil-DNA N-glycosylase (UNG) has not been identiﬁed. UVA does not induce debromination of SBrdU either in free solution or in DNA.
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inosine. This observation indicates that ICL formation is favoured
by UVA-induced SIdU deiodination. Consistent with ICL formation,
FA cells are hypersensitive to both SBrdU/UVA and SIdU/UVA and
both treatments trigger FANCD2 ubiquitination [36]. ICL forma-
tion by these combinations is enhanced in D2O, indicating that it is
at least partially by Type II photosensitisation [36]. ICL formation
may also involve the highly reactive thiyl or 5-uracily radicals
(Fig. 3).
6. Collateral damage
6.1. DNA
With the lowest oxidation potential among canonical DNA nucleo-
bases, guanine is the most susceptible to damage by ROS. DNA 8-
oxoGua, the predominant product of 1O2-mediated DNA oxidation, is
present in cultured cells treated with 6-TG/UVA or azathioprine/UVA.
Approximately half of the 8-oxoGua is generated from DNA-incorpo-
rated 6-TG. The remainder is the product of ROS derived from the pool
of unincorporated 6-TG nucleotides [20]. The potential importance of
6-TG-mediated guanine oxidation is underlined by the observation that
increased urinary 8-oxodG levels are associated with skin cancer risk in
transplant patients taking azathioprine [68]. It is noteworthy in this
regard that the estimated oxidation potential of 6-TG is equal to or
lower than that of 2’-deoxyguanosine, suggesting that it may eﬀectively
act as a sink for oxidatively-generated damage in DNA 6-TG [54].
In contrast, treatment of cultured cells with combinations of low
dose (≤10 kJ/m2) UVA and thiopyrimidines does not generate ROS - at
least those detectable by the rather limited CM-H2DCFDA FACS assay -
and DNA S4T/UVA [62], and SIdU/UVA or SBrdU/UVA combinations
[36] are not associated with measurable increases in DNA 8-oxoGua
despite extensive toxicity.
UVA activated ﬂuoroquinolones are a source of ROS. They damage
DNA and induce oxidised pyrimidine and purine bases including 8-
oxoGua as a major photoproduct [69–71]. DNA 8-oxoGua levels vary
depending on the ﬂuoroquinolone [71]. In isolated DNA, UVA-acti-
vated ﬂuoroquinolones generate 1O2 and DNA 8-oxoGua in a Type II
photoreaction. In yeast, the combination of ruﬂoxacin (which has a
very low triplet energy and cannot induce T < > T CPDs) and UVA
induces predominantly G to T transversions, the characteristic muta-
tion associated with DNA 8-oxoGua. Conﬁrming the involvement of
DNA 8-oxoGua, ogg-1-/- strains in which the repair of these lesions is
defective, are hypersensitive to mutation by ruﬂoxacin/UVA [72]. In
general, however, triplet energy transfer to generate T < > T CPDs
appears to be the predominant mode of ﬂuoroquinolone-induced DNA
damage [71].
It is also worth mentioning that like many antibiotics, the ﬂuor-
oquinolones (so far demonstrated for norﬂoxacin and moliﬂoxacin)
induce oxidative stress that contributes to their bactericidal activity
[73]. This common oxidation-related toxicity occurs at least partly as a
consequence of oxidation of the guanine nucleotide pool and the
incorporation of 8-oxoGua into nucleic acids [74].
6.2. Protein
Cellular proteins are signiﬁcant targets for damage by ROS [75].
Oxidised proteins are relatively insoluble and the intracellular deposi-
tion of insoluble oxidised protein aggregates is associated with aging
and with several neurodegenerative and inﬂammatory disorders.
Largely overlooked by the DNA repair ﬁeld in the past, protein
oxidation is a signiﬁcant contributor to radiation-induced toxicity
and mutagenesis [76] and there is growing evidence that excessive
ROS can damage the human DNA repair proteome and compromise
DNA repair [61,65,77].
Amino acid side chains can be oxidised to generate protein
carbonyls (aldehydes and ketones) as stable products [78]. The sulfur
atoms of methionine and cysteine can be oxidised to the corresponding
sulfenic acids (-SOH), unstable products that either undergo disulﬁde
bond formation or further oxidation to sulﬁnic (-SO2) or sulfonic acid
(-SO3) derivatives [79]. ROS generated by UVA radiation cause
extensive protein oxidation that is signiﬁcantly ampliﬁed by exogenous
photosensitisers. 6-TG, ﬂuoroquinolones, riboﬂavin and FICZ all
increase susceptibility to UVA-induced protein carbonylation and thiol
oxidation by reactions that are at least partly 1O2 dependent [61,65,77]
(R.Brem, unpublished). Among the protein changes induced by these
treatments, crosslinking between the components of multisubunit DNA
repair complexes is particularly noteworthy. Photosensitiser-depen-
dent intersubunit crosslinking has been observed for the PCNA [80],
Ku [61], RPA [81] and MCM2-7 [77] DNA replication/repair com-
plexes.
7. DNA-protein crosslinks
UVA activation of DNA 6-TG also induces DPCs. In vitro experi-
ments demonstrated the slow formation of DPCs between 6-TG-
containing oligonucleotides and thiol or amino groups in oligopeptides
[82]. Crosslinking was dependent on 6-TG oxidation. It was induced by
UVA irradiation of the oligonucleotide and was optimal following
oxidation by MMPP, which is consistent with the involvement of
GSO3, a good leaving group in nucleophilic substitution reactions.
Low-dose UVA irradiation also induced extensive DNA-protein cross-
linking in cells containing DNA 6-TG [82]. DPC formation was rapid
suggesting that the mechanism diﬀers from that of in vitro cross-
linking. 2-D DIGE analysis identiﬁed the DNA repair/replication
proteins MSH2, PCNA, DDB-1 and MCM2 among the crosslinked
species.
DNA-incorporated 6-TG is an important contributor to UVA-
induced DPC formation in intact cells. DNA 6-TG serves as both a
target for crosslink formation and as a source of ROS. Conﬁrmation
that ROS also induce crosslinking between proteins and canonical DNA
nucleobases was obtained from a comparative proteomic analysis of
DPCs formed in cultured human cells treated with 6-TG or (the non
DNA-integrated) ciproﬂoxacin in combination with UVA [83]. Stable
isotope labelling with amino acids in cell culture (SILAC) and mass
spectrometry identiﬁed more than 2000 DNA-crosslinked proteins
most of which are involved in gene expression or DNA repair/
replication. Essential proteins in all of the known canonical DNA
repair pathways were represented among those crosslinked by 6-TG or
ciproﬂoxacin combined with UVA. Among these DNA repair proteins,
more than 75% were present in DPCs induced by both 6-TG+UVA and
ciproﬂoxacin+UVA (Table 1).
UVA irradiation of cells containing DNA SIdU or SBrdU also
generates DPCs [36]. Their formation and the crosslinked proteins
have not, however, been analysed in detail.
8. DNA damage, repair and cancer
8.1. Mutagenesis
One consequence of exposure to clinical photosensitisers and
sunlight is likely to be the continuous production of potentially
mutagenic DNA lesions. The chronic induction of DNA damage
eﬀectively mimics ineﬃcient DNA repair. The correlation between
ineﬀective DNA repair and cancer risk is exempliﬁed by the cancer
proneness of patients with xeroderma pigmentosum (defective NER),
DNA breakage syndromes (deﬁciencies in repair factors such as DNA
ligase IV, NBS or ATM), Fanconi Anemia, Lynch Syndrome (DNA
mismatch repair-deﬁcient) and MUTYH-associated polyposis (im-
paired DNA 8-oxoGua processing).
Damage to the proteome also compromises DNA repair eﬃciency
and photochemical oxidation of the PCNA, Ku, hOGG1, MUTYH and
RPA DNA repair proteins in cultured human cells is associated with the
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inhibition of their respective DNA repair pathways [61,65,77,80,81].
The UVA photosensitisers we have considered here mimic and
amplify the eﬀects of their endogenous cellular counterparts.
Photosensitised UVA radiation and oxidative stress in general oxidises
DNA repair proteins and compromises DNA repair in human cells.
UVA is ﬁrmly implicated in the photosensitivity of, and the hugely
increased incidence of skin cancer in patients taking azathioprine
[21,84] and it is likely that inhibition of NER caused by the interaction
between DNA 6-TG and UVA is a contributory factor. It is signiﬁcant in
this regard that sequencing studies indicate that skin tumors [85–88]
and even normal sun-exposed skin [89] accumulate very high numbers
of mutations that bear the signature of UVB-induced DNA lesions that
are substrates for removal by NER. These unexpectedly high muta-
tional burdens suggest that chronic, low-level protein damage caused
by the UVA component of solar radiation may reduce the eﬃciency of
NER and contribute to the development of skin cancer.
8.2. Chemotherapy
The introduction of potentially lethal DNA lesions remains a
mainstay of chemotherapy. The synergistic lethality of UVA and the
thiopyrimidines has led to suggestions that S4dT, SIdU or SBrdU
treatment combined with low dose UVA might represent a useful
photochemotherapeutic strategy [22,23]. Indeed, a preliminary study
of the eﬀects of combined intravenous S4dT and ﬁber optic UVA in an
orthotopic rat bladder tumor model indicated that this might represent
a viable therapeutic option [90]. Recent studies indicate that 2,4-
dithiothymine may oﬀer an improved phototherapeutic option because
of its longer activation wavelength (aﬀording greater tissue penetra-
tion) and higher triplet and 1O2 yields [26,27]. These properties are
shared by 2,4-dithiouracil and this has led to the recent suggestion that
it may represent a potential RNA-targeted phototherapeutic agent [91].
DNA repair eﬃciency is an important determinant of tumor
responsiveness. The excellent response of testicular tumors to cisplatin
is partly due to their relatively ineﬃcient NER [92]. Similarly, the
favourable response of BRCA1-mutated breast carcinomas to
poly(ADP-ribose) polymerase (PARP) inhibitors reﬂects the ampliﬁed
toxicity of DNA breaks that accumulate owing to defective recombina-
tional DNA repair [93]. Tumor cells are frequently in a state of
oxidative stress and this may contribute to a favourable response to
chemotherapy. The toxicity of platinum drugs, for example, is en-
hanced by the increased oxidative stress induced by parenteral
ascorbate treatment [94] or by depletion of cellular NADPH [95], the
main cellular reducing agent. Indeed, carboplatin-based chemotherapy
combined with simultaneous oxidative stress results in improved
responses in ovarian cancer patients [94]. Photochemotherapeutic
approaches that ally induced oxidative stress to the induction of
potentially toxic DNA lesions would represent a two-pronged attack
on malignancies: induction of DNA damage and inhibition of repair.
In summary, it seems necessary to take a holistic view when
analysing the biological eﬀects of photosensitisers. In addition to the
obvious importance of DNA lesion induction, the possible amplifying
eﬀect of damage to the DNA repair proteome that normally avert the
consequences of those lesions should also be considered.
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